DOCSLIB.ORG

Cardiotoxicity of Amitriptyline and Doxepin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cardiotoxicity of Amitriptyline and Doxepin UCLA UCLA Previously Published Works Title Cardiotoxicity of amitriptyline and doxepin. Permalink https://escholarship.org/uc/item/80v5m0x9 Journal Clinical pharmacology and therapeutics, 29(3) ISSN 0009-9236 Authors Tobis, JM Aronow, WS Publication Date 1981-03-01 DOI 10.1038/clpt.1981.49 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Cardiotoxicity of amitriptyline and doxepin The cardiotoxicity of the tricyclic antidepressants amitriptyline and doxepin were compared in an animal with acute overdose. The mean repetitive extrasystole threshold (RET) decreased 71.5% with amitriptyline and 27.5% with doxepin (mean blood levels 933 nglml and 1889 nglm1). Physostigmine reversed these effects. Sodium bicarbonate had a variable effect on the lowered RET. The toxic arrhythmogenic effects of the tricyclic antidepressants can be measured by RET and are partly reversed by autonomic tone manipulation. In the same blood level range, doxepin is less toxic than amitriptyline. Jonathan M. Tobis, M.D., and Wilbert S. Aronow, M.D. Irvine, Calif Department of Medicine, University of California There is controversy over the relative car- Because of the life-threatening effects of diotoxicity of various tricyclic antidepressant overdose in humans, we were limited to the drugs.° Some believe that doxepin is less car- animal model to analyze the effect of amitrip- diotoxic than amitriptyline or imipramine.8 On tyline and doxepin overdose on repetitive ex- the other hand, there are several reports of fatal trasystole threshold (RET). We chose a dog intoxication from doxepin alone.' Vohra et al.' with acute drug overdose and constantly infused studied the effects on bundle of His conduction drug to maintain blood levels at toxic concen- of several tricyclic antidepressants in overdose tration. Electrical vulnerability was tested by victims.' They found prolonged HV conduction measuring ventricular fibrillation threshold di- time in seven of eight patients who had taken rectly or by measuring the current required to nortriptyline, amitriptyline, or imipramine but produce a repetitive extrasystole. Matta et al.6 normal bundle of His studies in six patients af- found that the RET is a good marker of the ter doxepin. Most of the deaths from tricyclic ventricular fibrillation threshold in 91% of the antidepressant overdose are from ventricular dogs they studied; single repetitive extrasystoles tachycardia that develops into ventricular fibril- occurred when 66% of the fibrillation current lation. Conduction abnormalities demonstrated was delivered and multiple extrasystoles at 82% by His studies suggest that electrical vulner- of the fibrillation current. In those animals with ability to ventricular tachycardia may be a dis- a significant fall in RET (taken arbitrarily as tinct characteristic. We therefore examined the >50% reduction in RET from baseline), several effect of amitriptyline and doxepin on electrical potential antidotes to the cardiotoxicity of instability. tricyclic antidepressants were tested. We have reported on the effect of amitriptyline on RET and its reversibility with sodium bicarbonate, Received for publication Oct. 27, 1980. physostigmine, propranolol, or left stellate Accepted for publication Nov. 18, 1980. ganglionectomy .7 We report here on our com- Reprint requests to: Jonathan M. Tobis, M.D., University of California, Irvine, 101 City Dr. South, Orange, CA 92668. parison of the effect of doxepin on electrical 0009-9236/81/030359+06$00.60/0 C) 1981 The C. V. Mosby Co. 359 360 Tobis and Aronovv Clin Pharmacol. Ther. March 1981 40- Table I. Effect of doxepin on RET and doxepin blood levels 36 - R ET Doxepin RET after doxepin blood level control (mA) (tnA) (ng Iml 32- Group A* 33.3 ± 4.7 31.4 7.2 1,614 ± 785 28 Group Bt 33.0 4.5 6.8 3.9t 2,379 921§ 24 - *RET after doxepin was not lowered more than 50% of control RET. tRET after doxepin was lowered more than 50% of control RET. < 0.01 RET before and after doxepin in group B. 20 - a §p < 0.05 Dozepin blood level reached in group B compared E _ with group A. 16 into the right femoral vein for injection of drugs. The left femoral artery was cannulated 12- with a 16-gauge polyethylene catheter and used to measure systemic blood pressure and to ob- 8- tain arterial blood samples. A Statham P23 Dc transducer and a Grass Polygraph recorder, were to 4 - Model 7, used record systemic blood pressure. An electrocardiogram was recorded on the Grass Polygraph using a standard limb lead. CONTROL AMITRIPTYLJNE DOXEPIN Electrical testing of the heart was performed Fig. 1. Comparison of amitriptyline and doxepin on as follows. The chest was opened by a thoracot- RET. omy on the right. Two Cordis sutureless epicar- dial electrodes, Model 324-856, were placed 2 vulnerability and the results of sodium bicar- cm apart on the right ventricle midway between bonate or physostigmine to reverse the car- the apex and the atrioventricular groove. The diotoxic effects. electrodes were connected through a stimulus isolation unit (Grass SIU-5A) and a constant Methods current unit (Grass CCU-1A) to a Grass S-44 We used 26 healthy mongrel dogs weighing square-wave pulse generator. The output of this 16 to 27 kg. Anesthesia was introduced in- assembly was calibrated with an oscilloscope. A travenously with sodium thiamylal 4 mg/kg and separate pacemaker was placed in line with the alpha chloralose 40 to 80 mg/kg at a concentra- Grass stimulator and was set at 200 beats per min tion of 5 mg/ml dissolved in heated normal to overcome any tachycardia induced by the an- saline. Additional alpha chloralose 20 to 50 ticholinergic effect of tricyclic antidepressants. mg/kg was given during the experiment if The heart was paced at 2 mA with a 2-msec necessary to maintain anesthesia. The dogs impulse. The pulse generator was able to deliver were intubated and ventilated with a Harvard a premature impulse with variable delay after the pump using a mixture of room air and 100% last paced beat. The pacemaker would then shut oxygen. The ventilator was adjusted to stabilize off for 3 sec, during which the effect of the the arterial blood pH at 7.30 to 7.45. Lights premature extrastimulus was observed on the were used to maintain body temperature. A electrocardiogram. 16-gauge polyethylene catheter was inserted The RET was obtained in the manner de- Volume 29 A mitriptyline and doxepin cardiotoxicitv 361 Number 3 scribed by Matta et al.6 Electrical diastole was 40-. scanned in 5-msec decrements, beginning at the end of the T wave and ending at the border of 36 - the strength interval curve, i.e., where no de- 32 polarization could be induced with the extrasys- tole. The current of the extrasystole impulses 28 - was set at 2 mA and was increased in incre- ments of 1 or 2 mA. The T wave was scanned at 24 - each successive current until a repetitive ex- trasystole was obtained. The RET was defined 20 - as the current required to induce at least one extra depolarization after the premature elec- 16 - trical input. The RET was verified by obtain- ing extrasystoles in at least two of three trials. 12 - The maximum output of our generator was 40 mA. 8 - Experimental interventions. After the base- 4 - line RET was obtained and reproduced 15 to 30 min later, amitriptyline or doxepin was infused. Each animal received only one of the drugs. CONTROL I BICARBONATE I COXEPIN Doxepin was given at a rate of 10 to 15 mg/kg A M ITR I PTYUNE CONTROL BICARBONATE over 30 min, followed by a constant infusion of Fig. 2. Comparison of amitriptyline and doxepin on 0.01 to 0.03 mg/kg/min. Amitriptyline was RET and effect of sodium bicarbonate in cases where given as an initial intravenous bolus of 3 to 10 fixed doses of drug decreased RET. mg/kg over 30 min, followed by constant infu- sion of 0.015 to 0.025 mg/kg/min. A constant Statistical analyses were by Student's t test for infusion was used to maintain blood levels. The paired or independent means. RET was obtained 15 min after the initial bolus and was verified as stable up to 60 min later. If Results the RET did not change significantly after the Three animals were tested for up to 3 hr for initial bolus, a second or even a third 10-mg/kg control levels and stability of the RET. The dose of drug was given. Blood levels of amitrip- baseline RET was 31 ± 1 mA and remained at tyline or doxepin were obtained at the time RET 30 ± 3 mA up to 3 hr later, with measurements was established. Blood levels were analyzed by taken every 30 to 60 min. After the control val- gas chromatography at Bio-Science Labor- ues were established in these three animals, 2 atories (Van Nuys, Calif.) mg physostigmine was given intravenously. The methods and results of administering po- The repeat mean RET was 30.6 ± 5.4 mA tential antidotes to amitriptyline have been re- (control not significantly different). For the ported.7 Ten dogs received doxepin. In those control animals and at various stages during the animals where the RET fell more than 50%, 44 intervention experiments, the ventricular fibril- mEq sodium bicarbonate was given intrave- lation threshold (VFT) was compared with the nously, and the RET was reperformed within 10 RET. The RET was 90.8% of the VFT. How- min. Arterial pH was measured before and after ever, during 1.5% of the trials the VFT oc- bicarbonate. In four dogs equilibrium was es- curred at the same current level as the RET.
Load more

Recommended publications
  • Medication: Amitriptyline 10 Mg
    Amitriptyline (Elavil) COMPLEX CHRONIC DISEASES PROGRAM Medication Handout Date: May 15, 2018 Medication: Amitriptyline 10 mg What is Amitriptyline? Amitriptyline belongs to a group of medications called tricyclic antidepressants (TCAs) that were first used to treat depression. It works by altering the levels of certain neuro- transmitters in the brain such as noradrenalin and serotonin. They have since been found to be effective for many different uses such as: pain, helping with sleep quality (but is not a sleeping pill), irritable bowel syndrome (with diarrhea), migraine prevention, and interstitial cystitis. Expected Benefit: Usually takes several weeks to notice a benefit You may not notice a benefit until you get to a dose of 25 mg Watch for possible side effects: This list of side effects is important for you to be aware of; however, it is also important to remember that not all side effects happen to all people. Many of these less serious side effects will improve over the first few days of taking the medications. If you have problems with these side effects talk with your doctor or pharmacist: Dry mouth – this is the most common side; the others are much less frequent Hangover effect – too sleepy in the morning Blurred vision Urinary retention, trouble with urination Tiredness, dizziness that is more than usual Diarrhea or constipation Stopping the medication: Do NOT stop taking this medication suddenly without asking your doctor – this medication is usually decreased slowly (at higher doses) before it is stopped completely How to use this medication: Take this medication with or without food Dosing Schedule: Start with 5 mg (½ tablet) 2 hrs before bed Increase dose according to table below Many patients can only tolerate 20 or 30 mg If you don’t have dry mouth or side effects, you can continue slowly increasing the dose to a maximum of 70 mg You can stay at a lower dose (stop increasing) if you get side effects (usually dry mouth).
    [Show full text]
  • PRODUCT MONOGRAPH ELAVIL® Amitriptyline Hydrochloride Tablets
    PRODUCT MONOGRAPH ELAVIL® amitriptyline hydrochloride tablets USP 10, 25, 50 and 75 mg Antidepressant AA PHARMA INC. DATE OF PREPARATION: 1165 Creditstone Road Unit #1 August 29, 2018 Vaughan, ON L4K 4N7 Control No.: 217626 1 PRODUCT MONOGRAPH ELAVIL® amitriptyline hydrochloride tablets USP 10, 25, 50, 75 mg THERAPEUTIC CLASSIFICATION Antidepressant ACTIONS AND CLINICAL PHARMACOLOGY Amitriptyline hydrochloride is a tricyclic antidepressant with sedative properties. Its mechanism of action in man is not known. Amitriptyline inhibits the membrane pump mechanism responsible for the re-uptake of transmitter amines, such as norepinephrine and serotonin, thereby increasing their concentration at the synaptic clefts of the brain. Amitriptyline has pronounced anticholinergic properties and produces EKG changes and quinidine-like effects on the heart (See ADVERSE REACTIONS). It also lowers the convulsive threshold and causes alterations in EEG and sleep patterns. Orally administered amitriptyline is readily absorbed and rapidly metabolized. Steady-state plasma concentrations vary widely and this variation may be genetically determined. Amitriptyline is primarily excreted in the urine, mostly in the form of metabolites, with some excretion also occurring in the feces. INDICATIONS AND CLINICAL USE ELAVIL® (amitriptyline hydrochloride) is indicated in the drug management of depressive illness. ELAVIL® may be used in depressive illness of psychotic or endogenous nature and in selected patients with neurotic depression. Endogenous depression is more likely to be alleviated than are other depressive states. ELAVIL® ®, because of its sedative action, is also of value in alleviating the anxiety component of depression. As with other tricyclic antidepressants, ELAVIL® may precipitate hypomanic episodes in patients with bipolar depression. These drugs are not indicated in mild depressive states and depressive reactions.
    [Show full text]
  • PERPHENAZINE and AMITRIPTYLINE HYDROCHLORIDE- Perphenazine and Amitriptyline Hydrochloride Tablet, Film Coated Mylan Pharmaceuticals Inc
    PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE- perphenazine and amitriptyline hydrochloride tablet, film coated Mylan Pharmaceuticals Inc. ---------- WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug- treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Perphenazine and amitriptyline hydrochloride is not approved for the treatment of patients with dementia- related psychosis (see WARNINGS). Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of perphenazine and amitriptyline or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.
    [Show full text]
  • Low-Dose Doxepin for Treatment of Pruritus in Patients on Hemodialysis
    DIALYSIS Low-Dose Doxepin for Treatment of Pruritus in Patients on Hemodialysis Fatemeh Pour-Reza-Gholi,1 Alireza Nasrollahi,2 Ahmad Firouzan,1 Ensieh Nasli Esfahani,1 Farhat Farrokhi3 1Department of Nephrology, Introduction. Pruritus is one of the frequent discomforting Shaheed Labbafinejad complications in patients with end-stage renal disease. We Medical Center & Urology and prospectively evaluated the effectiveness of doxepin, an H1-receptor Nephrology Research Center, antagonist of histamine, in patients with pruritus resistant to Shaheed Beheshti Medical University, Tehran, Iran conventional treatment. 2Department of Nephrology, Materials and Methods. A randomized controlled trial with a Shohada-e-Tajrish Hospital, crossover design was performed on 24 patients in whom other Shaheed Beheshti Medical etiologic factors of pruritus had been ruled out. They were assigned University, Tehran, Iran into 2 groups and received either placebo or oral doxepin, 10 mg, 3Urology and Nephrology Research Center, Shaheed twice a day for 1 week. After a 1-week washout period, the 2 groups Beheshti Medical University, were treated conversely. Subjective outcome was determined by Tehran, Iran asking the patients described their pruritus as completely improved, relatively improved, or remained unchanged/worsened. Keywords. pruritus, doxepin, Results. Complete resolution of pruritus was reported in end-stage renal disease, 14 patients (58.3%) with doxepin and 2 (8.3%) with placebo dialysis (P < .001). Relative improvement was observed in 7 (29.2%) and 4 (16.7%), respectively. Overall, the improving effect of doxepin on Original Paper pruritus was seen in 87.5% of the patients. Twelve patients (50.0%) complained of drowsiness that alleviated in all cases after 2 days in average.
    [Show full text]
  • Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice
    pharmaceuticals Article Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice Geng-Ruei Chang 1,* , Po-Hsun Hou 2,3, Wei-Cheng Yang 4, Chao-Min Wang 1 , Pei-Shan Fan 1, Huei-Jyuan Liao 1 and To-Pang Chen 5,* 1 Department of Veterinary Medicine, National Chiayi University, 580 Xinmin Road, Chiayi 60054, Taiwan; [email protected] (C.-M.W.); [email protected] (P.-S.F.); [email protected] (H.-J.L.) 2 Department of Psychiatry, Taichung Veterans General Hospital, 1650 Taiwan Boulevard (Section 4), Taichung 40705, Taiwan; [email protected] 3 Faculty of Medicine, National Yang-Ming University, 155 Linong Street (Section 2), Taipei 11221, Taiwan 4 School of Veterinary Medicine, National Taiwan University, 1 Roosevelt Road (Section 4), Taipei 10617, Taiwan; [email protected] 5 Division of Endocrinology and Metabolism, Show Chwan Memorial Hospital, 542 Chung-Shan Road (Section 1), Changhua 50008, Taiwan * Correspondence: [email protected] (G.-R.C.); [email protected] (T.-P.C.); Tel.: +886-5-2732946 (G.-R.C.); +886-4-7256166 (T.-P.C.) Abstract: Doxepin is commonly prescribed for depression and anxiety treatment. Doxepin-related disruptions to metabolism and renal/hepatic adverse effects remain unclear; thus, the underlying mechanism of action warrants further research. Here, we investigated how doxepin affects lipid Citation: Chang, G.-R.; Hou, P.-H.; change, glucose homeostasis, chromium (Cr) distribution, renal impairment, liver damage, and fatty Yang, W.-C.; Wang, C.-M.; Fan, P.-S.; liver scores in C57BL6/J mice subjected to a high-fat diet and 5 mg/kg/day doxepin treatment for Liao, H.-J.; Chen, T.-P.
    [Show full text]
  • Amitriptyline (Elavil): Important Patient Information
    What is most important to remember? If you have questions: Strong Internal Medicine • You must check to make sure that it is safe for you to take Ask your doctor, nurse or pharmacist for amitriptyline with all of your other more information about amitriptyline medicines and health problems (Elavil®). • Do not start any new medications, over-the-counter drugs or herbal remedies without talking to your doctor • Contact your prescriber If your symptoms or health problems do not get any better or they become worse • This medicine comes with an Strong Internal Medicine extra patient fact sheet called a 601 Elmwood Avenue Medication Guide. Read it with Ambulatory Care Facility, 5th Floor care. Read it again each time this Rochester, NY 14642 Phone: (585) 275 -7424 medicine is refilled Amitriptyline (Elavil®): • If you think there has been an Visit our website at: Important Patient Information www.urmc.rochester.edu/medicine/ - overdose, call your poison control general-medicine/patientcare/ center or get medical care right away What does amitriptyline (Elavil®) do? What side effects could occur with amitriptyline What are some things that I need to be aware of when • It belongs to a class of medications called tricyclic (Elavil®)? taking amitriptyline (Elavil®)? antidepressants (TCAs). It works by increasing the • Hard stools (constipation) • Tell your doctor or pharmacist if you are allergic to amitriptyline, any other medicines, foods, or substances amounts of certain natural substances in the brain that • Dizziness, feeling sleepy are needed
    [Show full text]
  • Association of Selective Serotonin Reuptake Inhibitors with the Risk for Spontaneous Intracranial Hemorrhage
    Supplementary Online Content Renoux C, Vahey S, Dell’Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published online December 5, 2016. doi:10.1001/jamaneurol.2016.4529 eMethods 1. List of Antidepressants for Cohort Entry eMethods 2. List of Antidepressants According to the Degree of Serotonin Reuptake Inhibition eMethods 3. Potential Confounding Variables Included in Multivariate Models eMethods 4. Sensitivity Analyses eFigure. Flowchart of Incident Antidepressant (AD) Cohort Definition and Case- Control Selection eTable 1. Crude and Adjusted Rate Ratios of Intracerebral Hemorrhage Associated With Current Use of SSRIs Relative to TCAs eTable 2. Crude and Adjusted Rate Ratios of Subarachnoid Hemorrhage Associated With Current Use of SSRIs Relative to TCAs eTable 3. Crude and Adjusted Rate Ratios of Intracranial Extracerebral Hemorrhage Associated With Current Use of SSRIs Relative to TCAs. eTable 4. Crude and Adjusted Rate Ratios of Intracerebral Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak eTable 5. Crude and Adjusted Rate Ratios of Subarachnoid Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak eTable 6. Crude and Adjusted Rate Ratios of Intracranial Extracerebral Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 eMethods 1.
    [Show full text]
  • 3,2,4 Tricyclic Antidepressants and the Risk of Congenital Malformation
    Tricyclic antidepressants and the risk of congenital malformations CONFIDENTIAL Medicines Adverse Reactions Committee Meeting date 3/12/2020 Agenda item 3.2.4 Title Tricyclic antidepressants and the risk of congenital malformations Submitted by Medsafe Pharmacovigilance Paper type For advice Team Active ingredient Product name Sponsor Amitriptyline Arrow-Amitriptyline Film coated tablet, 10 mg, 25 Teva Pharm (NZ) Ltd mg & 50 mg Amirol Film coated tablet, 10 mg & 25 mg AFT Pharmaceuticals Ltd Clomipramine Apo-Clomipramine Film coated tablet, 10 mg & Apotex NZ Ltd 25 mg Anafranil Tablet, 10 mg Section 29 Dosulepin Dosulepin Mylan Film coated tablet, 75 mg Mylan New Zealand Ltd Dosulepin Mylan Capsule, 25 mg Section 29 Doxepin Anten 50 Capsule, 50 mg Mylan New Zealand Ltd Imipramine Tofranil Coated tablet, 10 mg & 25 mg AFT Pharmaceuticals Ltd Nortriptyline Norpress Tablet, 10 mg & 25 mg Mylan New Zealand Ltd PHARMAC funding Product highlighted in bold above are funded on the Community Schedule. Two products (shown in italics) are funded but only available under Section 29 of the Medicines Act (ie, the products have not been approved by Medsafe). Previous MARC In utero exposure to serotonin reuptake inhibitors and risk of congenital meetings abnormalities 141st meeting March 2010 International action None Prescriber Update The use of antidepressants in pregnancy September 2010 Classification Prescription medicine Usage data The following pregnancy usage data for 2019 was obtained from the National Collections using the Pharmaceutical Dispensing in Pregnancy application in Qlik. The table shows the total number of dispensings, repeat dispensings and number of pregnancies exposed during first trimester (defined as 30 days prior to the estimated pregnancy start date to week 13) for pregnancies that ended in 2019.
    [Show full text]
  • Currently Prescribed Psychotropic Medications
    CURRENTLY PRESCRIBED PSYCHOTROPIC MEDICATIONS Schizophrenia Depression Anxiety Disorders 1st generation antipsychotics: Tricyclics: Atarax (hydroxyzine) Haldol (haloperidol), *Anafranil (clomipramine) Ativan (lorazepam) Haldol Decanoate Asendin (amoxapine) BuSpar (buspirone) Loxitane (loxapine) Elavil (amitriptyline) *Inderal (propranolol) Mellaril (thioridazine) Norpramin (desipramine) Keppra (levetiracetam) Navane (thiothixene) Pamelor (nortriptyline) *Klonopin (clonazepam) Prolixin (fluphenazine), Prolixin Sinequan (doxepin) Librium (chlordiazepoxide) Decanoate Spravato (esketamine) Serax (oxazepam) Stelazine (trifluoperazine) Surmontil (trimipramine) Thorazine (chlorpromazine) *Tenormin (atenolol) Tofranil (imipramine) MEDICATIONS PSYCHOTROPIC PRESCRIBED CURRENTLY Trilafon (perphenazine) Tranxene (clorazepate) Vivactil (protriptyline) Valium (diazepam) 2nd generation antipsychotics: Zulresso (brexanolone) Vistaril (hydroxyzine) Abilify (aripiprazole) Aristada (aripiprazole) SSRIs: Xanax (alprazolam) Caplyta (lumateperone) Celexa (citalopram) *Antidepressants, especially SSRIs, are also used in the treatment of anxiety. Clozaril (clozapine) Lexapro (escitalopram) Fanapt (iloperidone) *Luvox (fluvoxamine) Geodon (ziprasidone) Paxil (paroxetine) Stimulants (used in the treatment of ADD/ADHD) Invega (paliperidone) Prozac (fluoxetine) Invega Sustenna Zoloft (sertraline) Adderall (amphetamine and Perseris (Risperidone injectable) dextroamphetamine) Latuda (lurasidone) MAOIs: Azstarys(dexmethylphenidate Rexulti (brexpiprazole) Emsam (selegiline)
    [Show full text]
  • Doxepin (Silenor) for Insomnia DHIREN PATEL, Pharmd, and JENNIFER D
    STEPS New Drug Reviews Doxepin (Silenor) for Insomnia DHIREN PATEL, PharmD, and JENNIFER D. GOLDMAN-LEVINE, PharmD Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts STEPS new drug reviews Silenor is a new low-dose formulation of the tricyclic antidepressant doxepin (which is typi- cover Safety, Tolerability, cally taken as a 25- to 150-mg dose at bedtime). Low-dose doxepin is labeled for the treatment Effectiveness, Price, and Simplicity. Each indepen- of insomnia characterized by difficulty maintaining sleep. The exact mechanism by which the dent review is provided medication exerts its sleep maintenance effect is unknown, but is thought to be antagonism 1 by authors who have no of histamine H1 receptors. financial association with the drug manufacturer. The series coordinator for Drug Dosage Dose form Monthly cost* AFP is Allen F. Shaugh- nessy, PharmD, Tufts Doxepin (Silenor) 3 to 6 mg daily 3-mg and 6-mg tablets $208 University Family Medicine Residency Program at *—Price for 30 3-mg or 6-mg tablets at CVS Pharmacy on May 18, 2011. Cambridge Health Alli- ance, Malden, Mass. A collection of STEPS pub- lished in AFP is available SAFETY of 1,017 patients, approximately 1 percent at http://www.aafp.org/ 1 afp/steps. Doxepin is safe when used at low dosages. withdrew because of adverse effects. Rebound Antidepressants are required to have label- insomnia and withdrawal symptoms have not ing that warns of an increased risk of sui- been reported. Next-day sedation, anticholin- cide; however, there have been no reports ergic effects, and memory impairment do not of suicide among patients taking low-dose occur at low dosages.2,3 The use of central ner- doxepin.
    [Show full text]
  • High Degree of Efficacy in the Treatment of Cyclic Vomiting Syndrome with Combined Co-Enzyme Q10, L-Carnitine and Amitriptyline, a Case Series Richard G Boles1,2
    Boles BMC Neurology 2011, 11:102 http://www.biomedcentral.com/1471-2377/11/102 RESEARCHARTICLE Open Access High degree of efficacy in the treatment of cyclic vomiting syndrome with combined co-enzyme Q10, L-carnitine and amitriptyline, a case series Richard G Boles1,2 Abstract Background: Cyclic vomiting syndrome (CVS), defined by recurrent stereotypical episodes of nausea and vomiting, is a relatively-common disabling and historically difficult-to-treat condition associated with migraine headache and mitochondrial dysfunction. Limited data suggests that the anti-migraine therapies amitriptyline and cyproheptadine, and the mitochondrial-targeted cofactors co-enzyme Q10 and L-carnitine, have efficacy in episode prophylaxis. Methods: A retrospective chart review of 42 patients seen by one clinician that met established CVS diagnostic criteria revealed 30 cases with available outcome data. Participants were treated on a loose protocol consisting of fasting avoidance, co-enzyme Q10 and L-carnitine, with the addition of amitriptyline (or cyproheptadine in those < 5 years) in refractory cases. Blood level monitoring of the therapeutic agents featured prominently in management. Results: Vomiting episodes resolved in 23 cases, and improved by > 75% and > 50% in three and one additional case respectively. Among the three treatment failures, two could not tolerate amitriptyline (as was also the case in the child with only > 50% efficacy) and one had multiple congenital gastrointestinal anomalies. Excluding the latter case, substantial efficacy (> 75% response) was 26/29 at the start of treatment, and 26/26 in those able to tolerate the regiment, including high dosages of amitriptyline. Conclusion: Our data suggest that a protocol consisting of mitochondrial-targeted cofactors (co-enzyme Q10 and L-carnitine) plus amitriptyline (or possibly cyproheptadine in preschoolers) coupled with blood level monitoring is highly effective in the prevention of vomiting episodes.
    [Show full text]
  • DOXEPIN CREAM 5% (Prudoxin, Zonalon) RATIONALE FOR
    DOXEPIN CREAM 5% (Prudoxin, Zonalon) RATIONALE FOR INCLUSION IN PA PROGRAM Background Doxepin cream is a topical medication used for the short-term treatment of pruritus (itching of the skin) due to atopic dermatitis (eczema) or lichen simplex chronicus (thickening of skin due to prolonged itching and scratching). Although doxepin does have H1 and H2 histamine receptor blocking actions, the exact mechanism by which doxepin exerts its antipruritic effect is unknown. Possible adverse reactions include, but are not limited to: drowsiness, urinary retention, increased pruritus, and contact sensitization (1-2). Regulatory Status FDA-approved indications: Doxepin cream 5% is indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus (1-2). Doxepin has an anticholinergic effect and significant plasma levels of doxepin are detectable after topical doxepin cream application, the use of doxepin cream is contraindicated in patients with untreated narrow angle glaucoma or a tendency to urinary retention (1-2). A thin film of doxepin cream should be applied four times each day with at least a 3 to 4 hour interval between applications. There are no data to establish the safety and effectiveness of doxepin cream when used for greater than 8 days. Chronic use beyond eight days may result in higher systemic levels and should be avoided (1-2). Doxepin cream 5% criteria was created with dosing above FDA recommended limits in order to help existing patients that have been taking doses above the FDA recommended limits to safely taper down their doses to the appropriate levels.
    [Show full text]